Noxopharm Limited (NOXOF)

0,0300 0,0000 (0,00%) Ab 11:46AM EDT. Markt geöffnet.

Noxopharm Limited

60 Linksley Avenue
Glenhaven, NSW 2156
Australia

https://www.noxopharm.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Gisela Mautner	CEO, Executive MD & Director	316,52k	N/A	N/A
Mr. Shawn Van Boheemen FCPA, J.P.	Chief Financial Officer	N/A	N/A	N/A
Ms. Jeanette Bell Ph.D.	Chief Operating Officer	N/A	N/A	N/A
Dr. John Wilkinson B.Sc., Ph.D.	Chief Scientific Officer of Oncology	N/A	N/A	N/A
Dr. Olivier Laczka B.S., M.Sc., Ph.D.	Chief Scientific Officer of Inflammation	N/A	N/A	N/A
Mr. David James Franks BEc, C.A., F Fin, J.P.	Company Secretary	N/A	N/A	1970

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions; and Sofra platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases. The company was incorporated in 2015 and is based in Glenhaven, Australia.

Corporate Governance

Noxopharm Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.